Answers are grounded in this paper and cite their sources.
This randomized trial investigates BTK degradation effects on resistance in lymphoid malignancies, suggesting new treatment pathways.
After more than a decade of clinical experience with BTK inhibitors, resistance to BTK targeting has become a moving target, shaped by drug-specific BTK mutations, downstream signaling escape, and disease-dependent adaptive programs. The arrival of BTK degraders introduces a mechanistically distinct modality for lymphoid malignancies, but also raises a timely question: does degrading BTK rewrite the rules of resistance, or simply redraw its boundaries?
No takes yet. Share an insight, caveat, or question.
Arribas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: